SBI Okasan Asset Management Co.Ltd. Makes New $1.43 Million Investment in Elevance Health, Inc. $ELV

SBI Okasan Asset Management Co.Ltd. acquired a new stake in shares of Elevance Health, Inc. (NYSE:ELV) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,100 shares of the company’s stock, valued at approximately $1,428,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Sound View Wealth Advisors Group LLC boosted its stake in shares of Elevance Health by 3.0% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock valued at $354,000 after purchasing an additional 29 shares during the period. Fulton Breakefield Broenniman LLC boosted its stake in shares of Elevance Health by 3.6% during the fourth quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company’s stock valued at $289,000 after purchasing an additional 29 shares during the period. Perigon Wealth Management LLC boosted its stake in shares of Elevance Health by 2.2% during the fourth quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company’s stock valued at $481,000 after purchasing an additional 29 shares during the period. Savvy Advisors Inc. boosted its stake in shares of Elevance Health by 3.2% during the fourth quarter. Savvy Advisors Inc. now owns 979 shares of the company’s stock valued at $343,000 after purchasing an additional 30 shares during the period. Finally, CoreCap Advisors LLC boosted its stake in shares of Elevance Health by 6.1% during the fourth quarter. CoreCap Advisors LLC now owns 557 shares of the company’s stock valued at $195,000 after purchasing an additional 32 shares during the period. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Price Performance

ELV opened at $392.47 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $408.00. The stock has a market capitalization of $85.23 billion, a PE ratio of 16.69, a price-to-earnings-growth ratio of 2.21 and a beta of 0.66. The stock’s 50 day moving average price is $341.76 and its 200-day moving average price is $338.51.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. During the same period in the previous year, the firm earned $11.97 earnings per share. The business’s revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities research analysts predict that Elevance Health, Inc. will post 26.93 EPS for the current year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. Elevance Health’s payout ratio is 29.26%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ELV. Weiss Ratings raised Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, May 18th. Jefferies Financial Group dropped their price objective on Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Guggenheim increased their price objective on Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Truist Financial dropped their price objective on Elevance Health from $390.00 to $375.00 and set a “buy” rating for the company in a research note on Monday, April 13th. Finally, Leerink Partners set a $364.00 target price on Elevance Health in a research note on Thursday, April 23rd. Fourteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Elevance Health presently has a consensus rating of “Moderate Buy” and an average price target of $403.11.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.